Rep. Julie Johnson Unloads Johnson & Johnson (NYSE:JNJ) Shares

Representative Julie Johnson (D-Texas) recently sold shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on December 11th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on November 13th. The trade occurred in the Representative’s “CHASE BROKERAGE ACCOUNT (3935)” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Cigna Group (NYSE:CI) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Xcel Energy (NASDAQ:XEL) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Capital One Financial (NYSE:COF) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Wells Fargo & Company (NYSE:WFC) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 11/13/2025.
• Sold $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 11/13/2025.

Johnson & Johnson Stock Down 1.0%

JNJ opened at $208.23 on Friday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $215.18. The business has a 50-day moving average of $197.78 and a two-hundred day moving average of $178.67. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The stock has a market capitalization of $501.68 billion, a price-to-earnings ratio of 20.10, a price-to-earnings-growth ratio of 2.28 and a beta of 0.36.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. On average, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.5%. Johnson & Johnson’s dividend payout ratio is 50.19%.

Analysts Set New Price Targets

Several research analysts recently weighed in on JNJ shares. JPMorgan Chase & Co. increased their target price on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 16th. Raymond James Financial lifted their price objective on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday, October 15th. Loop Capital set a $190.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 22nd. BMO Capital Markets reiterated an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, December 11th. Finally, Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $210.25.

Institutional Investors Weigh In On Johnson & Johnson

Large investors have recently added to or reduced their stakes in the stock. Advisors Management Group Inc. ADV boosted its holdings in shares of Johnson & Johnson by 2.6% during the third quarter. Advisors Management Group Inc. ADV now owns 29,561 shares of the company’s stock valued at $5,481,000 after acquiring an additional 736 shares during the period. AIA Group Ltd increased its holdings in shares of Johnson & Johnson by 70.5% in the 3rd quarter. AIA Group Ltd now owns 112,856 shares of the company’s stock worth $20,926,000 after acquiring an additional 46,682 shares during the period. Financial Symmetry Inc bought a new stake in Johnson & Johnson in the 3rd quarter valued at about $346,000. Garde Capital Inc. boosted its stake in Johnson & Johnson by 6.4% during the 3rd quarter. Garde Capital Inc. now owns 1,925 shares of the company’s stock valued at $357,000 after purchasing an additional 116 shares during the period. Finally, Mirabella Financial Services LLP grew its position in Johnson & Johnson by 150.2% in the 3rd quarter. Mirabella Financial Services LLP now owns 14,161 shares of the company’s stock worth $2,621,000 after purchasing an additional 8,501 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.